A PYMNTS Company

U.S.: PhRMA accuses FTC of discriminating against industry

By  |  November 2, 2012

In response to the Federal Trade Commission’s decision to expand its jurisdiction over approving different types of exclusive pharmaceutical patent rights licenses, Pharmaceutical Research and Manufacturers of America has accused the FTC of exceeding its authority. Additionally, PhRMA has called for the FTC to dismiss the decision, arguing it discriminates against the pharmaceutical industry, and has asked the authority to change its premerger notification rules.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Law360

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.